Even though MALT1 exhibits two distinct molecular functions that lead either to IKK activation (scaffold function) or to the cleavage of selected substrates (protease function), the inhibition of MALT1 protease activity is sufficient to reduce tumor cell proliferation and apoptosis resistance in DLBCL, MCL, PEL, ATLL, MALT, and T-cell acute lymphoblastic leukemia (T-ALL), highlighting the therapeutic potential of MALT1 inhibitors in these hematological malignancies [70,76,77,78,79,80,81]. This evidence concerns the gene MALT1 and diffuse large B-cell lymphoma.